

# MORPHOSYS: BIRTH OF A BIOTECH

**1992**

Company founded in Munich, Germany

**1999**

IPO at the Frankfurt Stock Exchange

Start of an extensive partnership with Bayer AG

**2001**

Start of a strategic partnership with Schering AG

**2004**

Start of a strategic partnership with Novartis

**2006**

Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer's disease are used in clinics

**2009**

MorphoSys signs first infectious disease alliance with Daiichi-Sankyo

**2012**

MorphoSys announces positive clinical data in rheumatoid arthritis and chronic lymphocytic leukemia

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

**2014**

MorphoSys and Merck Serono enter strategic immuno-oncology collaboration

MorphoSys and Emergent BioSolutions sign license agreement to co-develop and commercialize prostate drug candidate

**2017**

Tremfya is approved for plaque psoriasis in the US, Europe and Canada

MorphoSys receives FDA breakthrough therapy designation for its proprietary lymphoma antibody for R/R DLBCL

**1997**

First commercial partnership with Pharmacia-Upjohn

**2000**

Presentation of the HuCAL antibody library

First HuCAL patent granted

**2003**

Start of a partnership with Pfizer  
HuCAL antibodies to combat Alzheimer's produce positive preclinical results

**2005**

Acquisition of Biogenesis Group strengthens research segment

**2007**

MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry's largest pharma-biotech R&D collaborations

**2011**

MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia

**2013**

MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program

MorphoSys signs strategic alliance with Celgene for MOR202 program

MorphoSys collaborator Novartis starts pivotal study with bimagrumab

**2016**

MorphoSys licensee Janssen submits an application seeking approval of guselkumab for the treatment of plaque psoriasis in the US and Europe

**2018**

MorphoSys IPO at Nasdaq

